NIA Looks to Combat Aging with New Clinical Trials

Getting old stinks, mostly because with age comes a variety of ailments. Currently, companies that develop rejuvenation biotechnology interventions have to target individual diseases to gain FDA approval. However, a recent Lifespan.io article discussed the National Institutes of Aging’s (NIA) funding of new clinical trials against aging itself. This is an important distinction because the trials are for interventions that directly affected the root causes of age-related diseases rather than the disease itself.